@article{3063719,
    title = "Commentary on the MID3 good practices paper",
    author = "Manolis, E. and Brogren, J. and Cole, S. and Hay, J.L. and Nordmark, A. and Karlsson, K.E. and Lentz, F. and Benda, N. and Wangorsch, G. and Pons, G. and Zhao, W. and Gigante, V. and Serone, F. and Standing, J.F. and Dokoumetzidis, A. and Vakkilainen, J. and Van Den Heuvel, M. and Sanjuan, V.M. and Taminiau, J. and Kerwash, E. and Khan, D. and Musuamba, F.T. and Rusten, I.S.",
    journal = "CPT - Pharmacometrics and Systems Pharmacology",
    year = "2017",
    volume = "6",
    number = "7",
    pages = "416-417",
    publisher = "American Society for Clinical Pharmacology and Therapeutics",
    issn = "2163-8306",
    doi = "10.1002/psp4.12223",
    keywords = "documentation;  food and drug administration;  good clinical practice;  health care organization;  information model;  interpersonal communication;  knowledge;  language;  Model Informed Drug Discovery and Development;  prediction;  priority journal;  reassurance;  Review;  simulation;  uncertainty;  computer simulation;  drug development;  drug industry;  Europe;  theoretical model, Computer Simulation;  Drug Discovery;  Drug Industry;  Europe;  Models, Theoretical",
    abstract = "During the last 10 years the European Medicines Agency (EMA) organized a number of workshops on modeling and simulation, working towards greater integration of modeling and simulation (M&S) in the development and regulatory assessment of medicines. In the 2011 EMA - European Federation of Pharmaceutical Industries and Associations (EFPIA) Workshop on Modelling and Simulation, European regulators agreed to the necessity to build expertise to be able to review M&S data provided by companies in their dossier. This led to the establishment of the EMA Modelling and Simulation Working Group (MSWG). Also, there was agreement reached on the need for harmonization on good M&S practices and for continuing dialog across all parties. The MSWG acknowledges the initiative of the EFPIA Model-Informed Drug Discovery and Development (MID3) group in promoting greater consistency in practice, application, and documentation of M&S and considers the paper is an important contribution towards achieving this objective. © 2017 ASCPT All rights reserved."
}